Translational Therapeutics
|
Open Access
Featured
-
-
Clinical Study
| Open AccessMipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours
- D Mahalingam
- , G Wilding
- & M Carducci
-
Clinical Study
| Open AccessExposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
- M Zhu
- , R Tang
- & Y Zhang
-
Clinical Study
| Open AccessPharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer
- L Ansaloni
- , F Coccolini
- & M Zucchetti
-
Clinical Study
| Open AccessCombination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
- L Bazzola
- , C Foroni
- & D Generali
-
Translational Therapeutics
| Open AccessOral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
- J J M A Hendrikx
- , J S Lagas
- & A H Schinkel
-
Clinical Study
| Open AccessA phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
- C-C Lin
- , W-C Su
- & J C-H Yang
-
Clinical Study
| Open AccessPharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
- N A G Lankheet
- , J S L Kloth
- & N Steeghs
-
Clinical Study
| Open AccessA phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
- F A L M Eskens
- , P Tresca
- & V Dieras
-
Translational Therapeutics
| Open AccessPrediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
- M Wilbaux
- , E Hénin
- & B You
-
Short Communication
| Open AccessInhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations
- S Hu
- , R H J Mathijssen
- & A Sparreboom
-
Clinical Study
| Open AccessSLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours
- A Khatri
- , B W Williams
- & M N Kirstein
-
Clinical Study
| Open AccessA dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
- A Adenis
- , I Ray-Coquard
- & N Penel
-
Clinical Study
| Open AccessHigher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)
- S G Louie
- , B Ely
- & C D Blanke
-
Clinical Study
| Open AccessA multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
- D W Bowles
- , W W Ma
- & A Jimeno
-
Clinical Study
| Open AccessSunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
- M D Michaelson
- , A X Zhu
- & A B Schwarzberg
-
Clinical Study
| Open AccessA first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours
- M A Warso
- , J M Richards
- & T K Das Gupta
-
Clinical Study
| Open AccessDocetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
- N C Tebbutt
- , M M Parry
- & V J Gebski
-
Translational Therapeutics
| Open AccessDose banding as an alternative to body surface area-based dosing of chemotherapeutic agents
- E Chatelut
- , M L White-Koning
- & A Sparreboom
-
Clinical Study
| Open AccessA phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
- D S Boss
- , H Glen
- & T R J Evans
-
Clinical Study
| Open AccessFirst-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
- T A Yap
- , H Cortes-Funes
- & J A López-Martin
-
Clinical Study
| Open AccessRandomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
- J H Yi
- , J Lee
- & W K Kang
-
Clinical Study
| Open AccessPhase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
- E Brain
- , N Isambert
- & P Fumoleau
-
Clinical Study
| Open AccessPhase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
- E Dean
- , M R Middleton
- & M Ranson
-
Clinical Study
| Open AccessErlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
- A C Mita
- , K Papadopoulos
- & E K Rowinsky
-
Clinical Study
| Open AccessA randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma
- S O'Day
- , A Pavlick
- & P Ho
-
Translational Therapeutics
| Open AccessPhase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- G K Schwartz
- , P M LoRusso
- & P J O'Dwyer
-
Translational Therapeutics
| Open AccessPG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
- K Dredge
- , E Hammond
- & I Bytheway
-
Clinical Study
| Open AccessPhase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
- A R A Razak
- , S J Hotte
- & E A Eisenhauer
-
Clinical Study
| Open AccessA Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours
- R Plummer
- , R H Wilson
- & T Nishiya
-
Clinical Study
| Open AccessA phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
- I M E Desar
- , J N H Timmer-Bonte
- & C M L van Herpen
-
Translational Therapeutics
| Open AccessCentral nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
- R A Daniel
- , A L Rozanska
- & N J Curtin
-
Clinical Study
| Open AccessPhase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer
- T Conroy
- , Y Yataghène
- & A Adenis
-
Translational Therapeutics
| Open AccessPhase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
- I R H M Konings
- , M J A de Jonge
- & F A L M Eskens
-
Translational Therapeutics
| Open AccessA phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
- E Boven
- , C Massard
- & J C Soria
-
Clinical Study
| Open AccessOpen-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer
- N M Corcoran
- , C M Hovens
- & A J Costello
-
Clinical Study
| Open AccessA phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
- U Lassen
- , L R Molife
- & J S de Bono
-
Molecular Diagnostics
| Open AccessPazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
- C-F Xu
- , B H Reck
- & L Pandite
-
Letter to the Editor
| Open AccessImatinib plasma levels: correlation with clinical benefit in GIST patients
- N Widmer
- , L A Decosterd
- & T Buclin
-
Translational Therapeutics
| Open AccessPopulation pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer
- B Royer
- , W Yin
- & X Pivot